企業プロフィール
AC Immune 株価・ニュース・カタリスト
- ティッカー:
- ACIU
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Switzerland and listed in the U
株価パフォーマンス
2.53 USD (+1.61%)
終値
最終更新: 2026年8月17日
246M USD
時価総額
株価変動の要因
As of Aug 17, 2026, ACIU closed up 1.61% at $2.53. No new same-company headline was identified in the current news window.
企業概要
Precision Neurodegeneration
AC Immune develops therapeutics and diagnostics for neurodegenerative diseases driven by protein misfolding and inflammation. Its portfolio combines active immunotherapies, small molecules and PET imaging agents.
ACI-7104
ACI-7104 is an active immunotherapy targeting alpha-synuclein in early Parkinson’s disease. Interim Phase 2 VacSYn results showed strong immunogenicity and suggested a potential slowing of clinical progression.
Alzheimer’s Immunotherapies
ACI-24 is an anti-amyloid active immunotherapy in the Phase 2 ABATE trial, while ACI-35 targets pathological tau. Both programs form part of AC Immune’s partnered clinical-stage vaccine portfolio.
Morphomer Small Molecules
The Morphomer platform creates brain-penetrant small molecules targeting intracellular protein pathology. Programs include tau aggregation inhibitors and ACI-19764, an NLRP3 inflammasome inhibitor now in Phase 1 testing.
Diagnostic Tracers
AC Immune also develops PET tracers for neurodegenerative pathology, including TDP-43. These tools could improve patient selection and disease monitoring in conditions that currently lack specific imaging biomarkers.
今後のカタリスト
- Interim Phase 2 ABATE results from the ACI-24 AD3 cohort expected in the first half of 2026.
- Final Part 1 VacSYn data for ACI-7104 expected in mid-2026, including full 24-month data in the third quarter.
- IND-enabling studies for the Morphomer-Tau program expected to begin in the first half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。